D
Ocular Therapeutix, Inc.
OCUL
$7.45
-$0.49-6.17%
D
Sell
5/9/2024Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D- from E+ on 5/9/2024 due to a large increase in the solvency index and valuation index. The quick ratio increased from 6.36 to 20.97, and debt to equity declined from 0.84 to 0.17.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D- from E+ on 5/9/2024 due to a large increase in the solvency index and valuation index. The quick ratio increased from 6.36 to 20.97, and debt to equity declined from 0.84 to 0.17.
E
Sell
5/15/2023Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to E+ from D- on 5/15/2023 due to a major decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.57 to 5.82, earnings per share declined from -$0.2369 to -$0.3918, and operating cash flow declined 17.78% from -$16.96M to -$19.97M.
Ocular Therapeutix, Inc. (OCUL) was downgraded to E+ from D- on 5/15/2023 due to a major decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.57 to 5.82, earnings per share declined from -$0.2369 to -$0.3918, and operating cash flow declined 17.78% from -$16.96M to -$19.97M.
D
Sell
3/14/2023Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and total return index. Debt to equity increased from 1.19 to 1.57, and the quick ratio declined from 4.81 to 3.94.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and total return index. Debt to equity increased from 1.19 to 1.57, and the quick ratio declined from 4.81 to 3.94.
D
Sell
2/23/2023Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index, solvency index and total return index. Debt to equity increased from 0.83 to 1.19, and the quick ratio declined from 5.94 to 4.81.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index, solvency index and total return index. Debt to equity increased from 0.83 to 1.19, and the quick ratio declined from 5.94 to 4.81.
D
Sell
5/31/2022Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
D
Sell
5/13/2022Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.6 to 0.67.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.6 to 0.67.
D
Sell
5/5/2022Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 16.72% from -$12.98M to -$15.15M.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 16.72% from -$12.98M to -$15.15M.
D
Sell
11/9/2021Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 11/9/2021 due to an increase in the solvency index, growth index and total return index. Operating cash flow increased 35.27% from -$20.06M to -$12.98M, earnings per share increased from -$0.2532 to -$0.23, and debt to equity declined from 0.64 to 0.6.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 11/9/2021 due to an increase in the solvency index, growth index and total return index. Operating cash flow increased 35.27% from -$20.06M to -$12.98M, earnings per share increased from -$0.2532 to -$0.23, and debt to equity declined from 0.64 to 0.6.
D
Sell
11/8/2021Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.59 to 0.64.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.59 to 0.64.
D
Sell
3/12/2021Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D from D+ on 3/12/2021 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.213 to -$1.2124, and EBIT declined 2.41% from -$14.01M to -$14.34M.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D from D+ on 3/12/2021 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.213 to -$1.2124, and EBIT declined 2.41% from -$14.01M to -$14.34M.
D
Sell
11/9/2020Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D+ from D on 11/9/2020 due to a substantial increase in the growth index, valuation index and total return index. Total revenue increased 274.51% from $1.57M to $5.88M, earnings per share increased from -$0.6374 to -$0.213, and EBIT increased 21.68% from -$17.88M to -$14.01M.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D+ from D on 11/9/2020 due to a substantial increase in the growth index, valuation index and total return index. Total revenue increased 274.51% from $1.57M to $5.88M, earnings per share increased from -$0.6374 to -$0.213, and EBIT increased 21.68% from -$17.88M to -$14.01M.
D
Sell
8/7/2020Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D from D+ on 8/7/2020 due to a noticeable decline in the growth index and valuation index. Earnings per share declined from -$0.4145 to -$0.6374, total revenue declined 39.86% from $2.61M to $1.57M, and EBIT declined 7.64% from -$16.61M to -$17.88M.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D from D+ on 8/7/2020 due to a noticeable decline in the growth index and valuation index. Earnings per share declined from -$0.4145 to -$0.6374, total revenue declined 39.86% from $2.61M to $1.57M, and EBIT declined 7.64% from -$16.61M to -$17.88M.
D
Sell
5/8/2020Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.5366 to -$0.4145, EBIT increased 22.37% from -$21.4M to -$16.61M, and total revenue increased 15.65% from $2.26M to $2.61M.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.5366 to -$0.4145, EBIT increased 22.37% from -$21.4M to -$16.61M, and total revenue increased 15.65% from $2.26M to $2.61M.
D
Sell
5/1/2020Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, total return index and valuation index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, total return index and valuation index.
D
Sell
8/2/2017Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 8/2/2017 due to a decline in the volatility index.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 8/2/2017 due to a decline in the volatility index.
D
Sell
7/18/2017Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 7/18/2017 due to an increase in the solvency index, valuation index and volatility index. The quick ratio increased from 8.24 to 9.31, and debt to equity declined from 0.3 to 0.28.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 7/18/2017 due to an increase in the solvency index, valuation index and volatility index. The quick ratio increased from 8.24 to 9.31, and debt to equity declined from 0.3 to 0.28.
D
Sell
3/10/2017Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/10/2017 due to a decline in the valuation index, solvency index and efficiency index. Net income declined 33.62% from -$9.6M to -$12.82M, debt to equity increased from 0.25 to 0.3, and total capital declined 13.09% from $77.84M to $67.65M.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/10/2017 due to a decline in the valuation index, solvency index and efficiency index. Net income declined 33.62% from -$9.6M to -$12.82M, debt to equity increased from 0.25 to 0.3, and total capital declined 13.09% from $77.84M to $67.65M.
D
Sell
2/17/2017Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 2/17/2017 due to an increase in the total return index, efficiency index and volatility index. Net income increased 16.16% from -$11.45M to -$9.6M.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 2/17/2017 due to an increase in the total return index, efficiency index and volatility index. Net income increased 16.16% from -$11.45M to -$9.6M.
D
Sell
5/11/2016Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 5/11/2016 due to a decline in the growth index, efficiency index and valuation index. Total capital declined 8.89% from $104.86M to $95.54M, operating cash flow declined 7.18% from -$8.64M to -$9.26M, and earnings per share declined from -$0.4301 to -$0.44.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 5/11/2016 due to a decline in the growth index, efficiency index and valuation index. Total capital declined 8.89% from $104.86M to $95.54M, operating cash flow declined 7.18% from -$8.64M to -$9.26M, and earnings per share declined from -$0.4301 to -$0.44.
D
Sell
3/28/2016Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 3/28/2016 due to an increase in the volatility index and total return index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 3/28/2016 due to an increase in the volatility index and total return index.
D
Sell
3/11/2016Downgrade
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.15 to 0.17.
Ocular Therapeutix, Inc. (OCUL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.15 to 0.17.
D
Sell
8/3/2015Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 8/3/2015 due to an increase in the valuation index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D from D- on 8/3/2015 due to an increase in the valuation index.
D
Sell
4/1/2015Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to D- from E+ on 4/1/2015 due to an increase in the total return index and volatility index.
Ocular Therapeutix, Inc. (OCUL) was upgraded to D- from E+ on 4/1/2015 due to an increase in the total return index and volatility index.
E
Sell
1/2/2015Upgraded
Ocular Therapeutix, Inc. (OCUL) was upgraded to E+ from E on 1/2/2015 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.46 to 23.96, and debt to equity declined from -0.21 to 0.23.
Ocular Therapeutix, Inc. (OCUL) was upgraded to E+ from E on 1/2/2015 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.46 to 23.96, and debt to equity declined from -0.21 to 0.23.
E
Sell
10/17/2014None
Ocular Therapeutix, Inc. (OCUL) was downgraded to E from U on 10/17/2014.
Ocular Therapeutix, Inc. (OCUL) was downgraded to E from U on 10/17/2014.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
